

September 25, 2017



## **Ensysce Biosciences Inc. to Present at 11th Annual Pain and Migraine Therapeutic Summit in San Diego, CA on September 27, 2017**

SAN DIEGO--(BUSINESS WIRE)-- Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences, Inc. has been invited to present at the **11<sup>th</sup> Annual Pain & Migraine Therapeutics Summit to be held September 27 and 28 in San Diego CA**. Dr. Kirkpatrick will present "Two-stage, GI Enzyme Activated Opioid Prodrugs and Combination Products for Abuse Prevention and Overdose Protection" at 3:15 PM PDT on Wednesday, September 27<sup>th</sup>. She will be discussing the recently completed clinical trial which demonstrated the safety and efficient oral activation of BIO-MD<sup>TM</sup> oxycodone prodrug, PF614. Ensysce's BIO-MD<sup>TM</sup> prodrug platform provides abuse deterrence for inhalation, injection and chewing of single agent products. The Human Abuse Liability approach to development will be reviewed along with the Multi-Pill Abuse Resistant (MPAR<sup>TM</sup>) technology overdose protection that can be applied to this pipeline of products.

### **About Ensysce Biosciences:**

Ensysce Biosciences, San Diego CA, is an integrated drug delivery company for both small and large molecules. The BIO-MD<sup>TM</sup> prodrug abuse deterrent and MPAR<sup>TM</sup> overdose resistant pain platforms of Ensysce eliminate the ability to abuse opioid products by the non-oral route, something that is the fastest growing drug problem in the US and that leads to billions in healthcare costs annually. The technology, with a worldwide intellectual patent protection, has been successfully validated in Phase 1 studies of the BIO-MD<sup>TM</sup> hydromorphone prodrug, PF329 and oxycodone prodrug, PF614.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170925005255/en/>

Ensysce Biosciences Inc.  
Dr. Lynn Kirkpatrick, 858-242-1553

Source: Ensysce Biosciences Inc.